Six injectable products will be launched in the Canada market shortly
Drug firm Caplin Point Laboratories has entered into a strategic partnership with Canada’s JAMP Pharma Group for six injectable products.
Caplin Steriles (a subsidiary of Caplin Point Laboratories) has partnered with JAMP Pharma Group for six injectable products to be filed shortly in Canada, Caplin Point Laboratories said in a regulatory filing.
Caplin Point Laboratories said some of these products have already been filed by Caplin Steriles in the US.
CC Paarthipan, Chairman, Caplin Point Laboratories said, “We have targeted Canada as one of our key expansion areas in regulated markets and we are excited to work with JAMP, one of the fastest-growing companies in Canada.”
Paarthipan said the company will add more products to this partnership in due course.
Louis Pilon, CEO, JAMP Pharma Group’s said this partnership will allow the companies to continue with its mission to provide more affordable options to Canadian patients, as well as our retail and institutional partners.
We certainly hope to collaborate on more products with our new partner in the coming years, he added.